Results 61 to 70 of about 19,015 (246)

Semaglutide for the treatment of obesity [PDF]

, 2022
Introduction and purpose Due to the growing tendency to diagnose obesity in patients, scientists are trying to find drugs that facilitate weight reduction.  An example of such a formulation is the GLP-1 analogue semaglutide. The following article is
Gras-Ozimek, Jordi, Kozińska, Iga, Kozińska, Urszula, Oleszczuk, Anna, Rafal   +4 more
core   +2 more sources

The complexity of dementia development and its comorbidities: The collaborative cross‐mouse population for multivarious tasks approach

Animal Models and Experimental Medicine, EarlyView.
The increasing prevalence of dementia and related neurodegenerative diseases—including Alzheimer's disease, Parkinson's disease, multiple sclerosis, and amyotrophic lateral sclerosis—poses a growing public health challenge. These conditions have traditionally been studied as isolated central nervous system disorders, but emerging evidence points to ...
Osayd Zohud, Iqbal M. Lone, Kareem Midlej, Fuad A. Iraqi   +3 more
wiley   +1 more source

Safety considerations of semaglutide in the potential treatment of Alzheimer's disease: A pooled analysis of semaglutide in adults aged ≥ 65 years

Alzheimer’s & Dementia: Translational Research & Clinical Interventions
INTRODUCTION The evoke/evoke+ trials are investigating semaglutide in a population with early Alzheimer's disease (AD). Specific analyses of semaglutide safety data in older adults are limited; therefore, in the current analysis, we aimed to evaluate ...
Marwan Sabbagh, Cristina Boschini, Sharon Cohen, Magnus Fugger, Frank Jessen, Sune Dandanell, Sue D. Pedersen, Luis Rafael Solís Tarazona, Vanita R. Aroda   +8 more
doaj   +1 more source

Potentiation of the restorative effect of semaglutide on metabolic and hormonal parameters in rats with diet-induced type 2 diabetes mellitus with intranasally administered insulin

Сибирский научный медицинский журнал
Semaglutide, a glucagon-like peptide-1 receptor agonist, is widely used for the treatment of type 2 diabetes mellitus (DM2), but it is not effective in some patients, which requires the development of approaches to enhance its therapeutic effect.
K. V. Derkach, N. E. Basova, A. O. Shpakov   +2 more
doaj   +1 more source

Glucagon-like peptide-1 and its class B G protein-coupled receptors: A long march to therapeutic successes [PDF]

, 2016
Theglucagon-likepeptide (GLP)-1receptor (GLP-1R) is a class B G protein-coupled receptor (GPCR) that mediates the action of GLP-1, a peptide hormone secretedfromthreemajor tissues inhumans,enteroendocrine L cells in the distal intestine, a cells in the ...
Adelhorst, Alastair J. H. Brown, Andersen, Avatapalle, Belin, Brown, Caihong Zhou, Chris de Graaf, Dan Donnelly, Davis, Dehua Yang, Denise Wootten, Denker, Dods, Drucker, Elahi, Ferguson, Gallwitz, Goodman, Green, Grynkiewicz, Gustavson, Göke, Hendrick, Heppner, Hjorth, Holst, Holst, Huang, Jendle, Jesper Lau, Jiayu Liao, Jiejie Deng, Jung-Mo Ahn, La Barre, Laurence J. Miller, Li, Locatelli-Hoops, Lund, Madeleine M. Fletcher, Ming-Wei Wang, Mojsov, Mojsov, Nauck, Nauck, Orskov, Orskov, Patrick M. Sexton, Pocai, Prentki, Rhodes, RICHARD DEQUAN YE, Sancho, Shiue, Steensgaard, Tang-Christensen, Tibaduiza, Tomkin, Unson, Wettergren, Widmann, Wild, Willard, Zunz   +63 more
core   +3 more sources

Decoding the Pathophysiology of Autoimmune Diseases—Mechanism, Triggers, and Nanotherapeutics: A Review

Advanced NanoBiomed Research, EarlyView.
This review highlights how autoimmune diseases arise from intertwined immunological, genetic, and environmental factors, emphasizing gut microbiota dysbiosis as a pivotal driver. It outlines emerging nanotechnology‐based strategies—such as liposomes, hydrogels, and polymeric nanoparticles—that enhance targeted drug delivery, minimize systemic toxicity,
Md. Meraj Ansari, Yunhui Min, Eun‐Ju Ko, Doyoung Kwon, Rehan Khan, Young‐Ok Son   +5 more
wiley   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Risk of Autoimmune Rheumatic Diseases

Arthritis &Rheumatology, Accepted Article.
Objective GLP‐1 receptor agonists (GLP‐1RAs) and SGLT2 inhibitors (SGLT2is) facilitate weight loss and exhibit immunomodulatory effects, but their impact on the risk of developing autoimmune rheumatic diseases (ARDs) is unclear. We compared ARD incidence following initiation of GLP‐1RAs, or SGLT2is, vs.
Derin Karacabeyli, Diane Lacaille, Na Lu, Hui Xie, J. Antonio Aviña‐Zubieta   +4 more
wiley   +1 more source

Trends in the utilization, expenditure and costs of noninsulin glucose‐lowering drugs in the Medicaid population: Steady increases in glucagon‐like peptide‐1 receptor agonist and sodium–glucose transporter‐2 inhibitor use, prices and expenditure

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to analyse changes in the utilization, expenditure and average cost of noninsulin glucose‐lowering drugs (GLDs) between 2008 and 2023. Methods This was a retrospective observational study of 2008–2023 data from the National Medicaid State Drug Utilization database.
Rawan O. Almadfaa
wiley   +1 more source

Impact of semaglutide on osteoarthritis risk in patients with obesity: A retrospective cohort study

Obesity Science & Practice
Background Osteoarthritis (OA) is a prevalent degenerative joint disorder. While the effect of obesity on OA is well documented, less is known about the effect of semaglutide on OA.
Onur Baser, Lauren Isenman, Sefika Baser, Gabriela Samayoa   +3 more
doaj   +1 more source

Characteristics and outcomes of diabetic patients with an implantable cardioverter defibrillator in a real world setting: results from the Israeli ICD registry [PDF]

, 2016
AIMS: There are limited data regarding the effect of diabetes mellitus (DM) on the risks of both appropriate and inappropriate implantable cardioverter defibrillator (ICD) therapy.
Alexander Tenenbaum, Alon Barsheshet, Boris Strasberg, Enrique Z. Fisman, Gregory Golovchiner, Hillel Steiner, Ilan Goldenberg, Mahmoud Suleiman, Michael Geist, Michael Glikson, Moshe Swissa, null null   +11 more
core   +1 more source